Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene clues could unlock better diagnosis for blood disorders

NCT ID NCT07298733

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two genes (IL-1β and IL-33) in 300 adults with low platelet counts caused by either primary immune thrombocytopenia (ITP) or lupus (SLE). Researchers will measure gene activity from a blood sample to see if these genes can help tell the two conditions apart. The goal is to find better ways to diagnose and understand these disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

It's a cross sectional study that will be carried out in the period from November 2025 to November 2026. * Groups: 1. Group A: Patients with newly diagnosed or chronic primary ITP. 2. Group B: Patients with SLE-associated thrombocytopenia. 3. Group C: Healthy controls (age- and sex-matched). Inclusion Criteria: * Adults (18-60 years). * Diagnosed primary ITP * Diagnosed SLE with thrombocytopenia Exclusion Criteria: * Patients on recent immunosuppressive therapy (\<4 weeks). * Co-existing infections, malignancies, or other autoimmune cytopenias. All patients will be subjected to : Sample Collection: * 5 ml peripheral blood collected under sterile conditions. * Separation of PBMCs (peripheral blood mononuclear cells). Laboratory Methods: 1. RNA Extraction: from PBMCs. 2. cDNA Synthesis: using reverse transcriptase. 3. Gene Expression Analysis: using Quantitative Real-Time PCR (qRT-PCR)

Ages

18 to 60 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adults (18-60 years). * Diagnosed primary ITP * Diagnosed SLE with thrombocytopenia Exclusion Criteria: * • Patients on recent immunosuppressive therapy (\<4 weeks). * Co-existing infections, malignancies, or other autoimmune cytopenias

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune thrombocytopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Inflammation Purpura, Thrombocytopenic, Idiopathic systemic lupus erythematosus thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immune thrombocytopenia System; lupus erythematosus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.